HDAC6 inhibitors and imaging agents
Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC. Methods for prepared unlabeled and labeled compounds, diagnostic methods, and methods of treating diseases associated HDAC are also provided.
1. A compound, which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition, comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
3. A method of inhibiting an activity of a histone deacetylase (HDAC) enzyme, comprising contacting the HDAC enzyme with a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the histone deacetylase (HDAC) enzyme is HDAC6.
5. The method of claim 3 , wherein the compound selectively inhibits HDAC6 over one or more of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, HDAC9, HDAC10, and HDAC11.
6. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt thereof.